• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

伊朗西北部散发性结直肠癌的一份新型基因突变报告。

A novel gene mutation report in sporadic colorectal cancer, from Northwest of Iran.

作者信息

Dolatkhah Roya, Somi Mohammad Hossein, Kermani Iraj Asvadi, Farassati Faris, Dastgiri Saeed

机构信息

Hematology and Oncology Research Center Tabriz University of Medical Sciences Tabriz Iran.

Liver and Gastrointestinal Diseases Research Center Tabriz University of Medical Sciences Tabriz Iran.

出版信息

Clin Case Rep. 2017 Feb 9;5(3):338-341. doi: 10.1002/ccr3.779. eCollection 2017 Mar.

DOI:10.1002/ccr3.779
PMID:28265402
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5331244/
Abstract

While the role of gene mutations has been widely accepted for predicting responses to anti-EGFR therapy in patients with colorectal cancer, although this study was based on observation of a single case it gives hope that some gene mutation may have favorable prognosis. More studies are required on patients with similar mutation to validate this finding.

摘要

虽然基因突变在预测结直肠癌患者抗表皮生长因子受体（EGFR）治疗反应中的作用已被广泛接受，但尽管本研究基于单个病例观察，它仍带来了一些基因突变可能具有良好预后的希望。需要对具有相似突变的患者进行更多研究以验证这一发现。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9c62/5331244/01be23e5bf16/CCR3-5-338-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9c62/5331244/52c4f7d27772/CCR3-5-338-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9c62/5331244/01be23e5bf16/CCR3-5-338-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9c62/5331244/52c4f7d27772/CCR3-5-338-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9c62/5331244/01be23e5bf16/CCR3-5-338-g002.jpg

相似文献

1
A novel gene mutation report in sporadic colorectal cancer, from Northwest of Iran.伊朗西北部散发性结直肠癌的一份新型基因突变报告。
Clin Case Rep. 2017 Feb 9;5(3):338-341. doi: 10.1002/ccr3.779. eCollection 2017 Mar.
2
Common KRAS and NRAS gene mutations in sporadic colorectal cancer in Northeastern Iranian patients.伊朗东北部散发性结直肠癌患者中常见的KRAS和NRAS基因突变
Curr Probl Cancer. 2018 Nov;42(6):572-581. doi: 10.1016/j.currproblcancer.2018.05.001. Epub 2018 May 25.
3
KRAS mutation detection in Tunisian sporadic coloractal cancer patients with direct sequencing, high resolution melting and denaturating high performance liquid chromatography.直接测序、高分辨率熔解和变性高效液相色谱法检测突尼斯散发性结肠直肠癌患者的 KRAS 突变。
Cancer Biomark. 2010;8(6):331-40. doi: 10.3233/CBM-2011-0222.
4
Systematic review: Anti-epidermal growth factor receptor treatment effect modification by KRAS mutations in advanced colorectal cancer.系统评价：KRAS 突变对晚期结直肠癌抗表皮生长因子受体治疗效果的影响。
Ann Intern Med. 2011 Jan 4;154(1):37-49. doi: 10.7326/0003-4819-154-1-201101040-00006.
5
Molecular Characterization of KRAS, BRAF, and EGFR Genes in Cases with Prostatic Adenocarcinoma; Reporting Bioinformatics Description and Recurrent Mutations.前列腺腺癌病例中KRAS、BRAF和EGFR基因的分子特征；报告生物信息学描述和复发性突变
Clin Lab. 2015;61(7):749-59. doi: 10.7754/clin.lab.2014.141210.
6
KRAS mutation testing of colorectal cancer for anti-EGFR therapy: dogmas versus evidence.结直肠癌抗 EGFR 治疗的 KRAS 基因突变检测：定论与证据。
Curr Cancer Drug Targets. 2010 Dec;10(8):813-23. doi: 10.2174/156800910793357989.
7
Combined analysis of specific KRAS mutation, BRAF and microsatellite instability identifies prognostic subgroups of sporadic and hereditary colorectal cancer.联合分析 KRAS 特定突变、BRAF 和微卫星不稳定性可识别散发性和遗传性结直肠癌的预后亚组。
Int J Cancer. 2010 Dec 1;127(11):2569-75. doi: 10.1002/ijc.25265.
8
Prognosis and clinical characteristics of colorectal cancer patients with KRAS gene mutation: a 5-year follow-up study.KRAS基因突变的结直肠癌患者的预后及临床特征：一项5年随访研究
Int J Clin Exp Pathol. 2019 Feb 1;12(2):409-418. eCollection 2019.
9
The association of clinicopathological features and survival in colorectal cancer patients with kras mutation status.结直肠癌患者KRAS突变状态与临床病理特征及生存情况的关联
J Cancer Res Ther. 2016 Jan-Mar;12(1):96-102. doi: 10.4103/0973-1482.148684.
10
Phosphoinositide-3-kinase catalytic alpha and KRAS mutations are important predictors of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced non-small cell lung cancer.磷酸肌醇 3-激酶催化亚单位α和 KRAS 突变是晚期非小细胞肺癌患者对表皮生长因子受体酪氨酸激酶抑制剂治疗产生耐药的重要预测因子。
J Thorac Oncol. 2011 Apr;6(4):707-15. doi: 10.1097/JTO.0b013e31820a3a6b.

引用本文的文献

1
Multifunctional nanomedicines for targeting epidermal growth factor receptor in colorectal cancer.用于结直肠癌细胞表皮生长因子受体靶向的多功能纳米药物。
Cell Mol Life Sci. 2020 Mar;77(6):997-1019. doi: 10.1007/s00018-019-03305-z. Epub 2019 Sep 28.
2
Main Risk Factors Association with Proto-Oncogene Mutations in Colorectal Cancer.与结直肠癌原癌基因突变相关的主要风险因素
Asian Pac J Cancer Prev. 2018 Aug 24;19(8):2183-2190. doi: 10.22034/APJCP.2018.19.8.2183.
3
The Role of Tumor Microenvironment in Chemoresistance: To Survive, Keep Your Enemies Closer.

本文引用的文献

1
Correlation between RAS Test Results and Prognosis of Metastatic Colorectal Cancer Patients: a Report from Western Iran.RAS检测结果与转移性结直肠癌患者预后的相关性：来自伊朗西部的报告
Asian Pac J Cancer Prev. 2016;17(4):1729-32. doi: 10.7314/apjcp.2016.17.4.1729.
2
G12V and G12A KRAS mutations are associated with poor outcome in patients with metastatic colorectal cancer treated with bevacizumab.G12V和G12A KRAS突变与接受贝伐单抗治疗的转移性结直肠癌患者的不良预后相关。
Tumour Biol. 2016 May;37(5):6823-30. doi: 10.1007/s13277-015-4523-7. Epub 2015 Dec 10.
3
Genetic pathways, prevention, and treatment of sporadic colorectal cancer.
肿瘤微环境在化疗耐药中的作用：为求生存，与敌人更亲近。
Int J Mol Sci. 2017 Jul 21;18(7):1586. doi: 10.3390/ijms18071586.
散发性结直肠癌的遗传通路、预防与治疗
Oncoscience. 2014 Jun 30;1(6):400-6. doi: 10.18632/oncoscience.59. eCollection 2014.
4
Novel KRAS gene mutations in sporadic colorectal cancer.散发性结直肠癌中的新型KRAS基因突变
PLoS One. 2014 Nov 20;9(11):e113350. doi: 10.1371/journal.pone.0113350. eCollection 2014.
5
454 next generation-sequencing outperforms allele-specific PCR, Sanger sequencing, and pyrosequencing for routine KRAS mutation analysis of formalin-fixed, paraffin-embedded samples.454 高通量测序在常规福尔马林固定石蜡包埋样本 KRAS 基因突变分析方面优于等位基因特异性 PCR、Sanger 测序和焦磷酸测序。
Onco Targets Ther. 2013 Aug 5;6:1057-64. doi: 10.2147/OTT.S42369. eCollection 2013.
6
Molecular pathways and cellular metabolism in colorectal cancer.结直肠癌中的分子通路与细胞代谢
Dig Surg. 2013;30(1):12-25. doi: 10.1159/000347166. Epub 2013 Apr 10.
7
Detection of low-abundance KRAS mutations in colorectal cancer using microfluidic capillary electrophoresis-based restriction fragment length polymorphism method with optimized assay conditions.采用优化实验条件的基于微流控毛细管电泳的限制片段长度多态性方法检测结直肠癌中低丰度 KRAS 突变。
PLoS One. 2013;8(1):e54510. doi: 10.1371/journal.pone.0054510. Epub 2013 Jan 23.
8
Cost-effectiveness analysis of screening for KRAS and BRAF mutations in metastatic colorectal cancer.转移性结直肠癌 KRAS 和 BRAF 突变筛查的成本效益分析。
J Natl Cancer Inst. 2012 Dec 5;104(23):1785-95. doi: 10.1093/jnci/djs433. Epub 2012 Nov 28.
9
Association of folate intake, dietary habits, smoking and COX-2 promotor -765G>C polymorphism with K-ras mutation in patients with colorectal cancer.叶酸摄入量、饮食习惯、吸烟及COX-2启动子-765G>C多态性与结直肠癌患者K-ras突变的相关性
J Egypt Natl Canc Inst. 2012 Sep;24(3):115-22. doi: 10.1016/j.jnci.2012.05.002. Epub 2012 Jul 4.
10
Clinical pharmacogenomic testing of KRAS, BRAF and EGFR mutations by high resolution melting analysis and ultra-deep pyrosequencing.采用高分辨率熔解分析和超深度焦磷酸测序法进行 KRAS、BRAF 和 EGFR 基因突变的临床药物基因组学检测。
BMC Cancer. 2011 Sep 24;11:406. doi: 10.1186/1471-2407-11-406.